CSL Behring submits BLA requesting approval of Human Fibrinogen Concentrate for the treatment of congenital bl
CSL Behring Submits BLA Requesting Approval of Human Fibrinogen Concentrate for the Treatment of Congenital Bl
CSL Behring Submits BLA Requesting Approval of Human Fibrinogen Concentrate for the Treatment of Congenital Bl
Archemix' blood disorder drug gets orphan drug status from EC
A Thought Leader Analysis Conference Examining Coagulants, Pricing, Gene Therapy and Third World Market Growth
Archemix' ARC1779 Granted Orphan Designation in EU for the Treatment of TTP, a Life-Threatening Blood Disorder
A Thought Leader Analysis Conference Examining Coagulants, Pricing, Gene Therapy and Third World Market Growth
A Thought Leader Analysis Conference Examining Coagulants, Pricing, Gene Therapy and Third World Market Growth
A Thought Leader Analysis Conference Examining Coagulants, Pricing, Gene Therapy and Third World Market Growth
A Thought Leader Analysis Conference Examining Coagulants, Pricing, Gene Therapy and Third World Market Growth
A Thought Leader Analysis Conference Examining Coagulants, Pricing, Gene Therapy and Third World Market Growth
A Thought Leader Analysis Conference Examining Coagulants, Pricing, Gene Therapy and Third World Market Growth
Research and Markets: A Thought Leader Analysis Conference Examining Coagulants, Pricing, Gene Therapy and Thi
First guideline released for von Willebrand Disease
Methods of treating hemophilia or von willebrand disease with p-selectin
Key Challenges and Issues facing the Blood Disorders Market Analysis and Forecasts Report to 2013
High peripheral artery disease prevalence in blacks still unexplained
Akt compositions for enhancing survival of cells
Method for diagnosis and treatment of haemophilia A patients with an inhibitor
Transdermal delivery system for dried particulate or lyophilized medications
